{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260602830373/en/Travere-Therapeutics-Enters-Into-Exclusive-Licensing-Agreement-with-Everest-Medicines-for-Civorebrutinib-a-Potential-Best-in-Class-BTK-Inhibitor-for-Rare-Kidney-Diseases", "message": "News view counter 773035 successfully enlarged"}